Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michael S. Firstenberg
Review of heart transplantation and left ventricular assist
Article Heart Transplant and Ventricular Assist: Cardiac Surgery and Heart Failure Perspective Abstract For nearly 60 years, there have been two surgical treatment options for individuals with severe advanced heart failure: heart transplantation or implantation of a left ventricular assist device. As these fields have advanced in parallel, improvements in surgical technique, device development, and patient selection have improved outcomes for both therapies.
Redwood-HCM: Second-Generation Drug for HCM Well-Tolerated by Patients
- I'm Marty Maron. I'm the Director for the Hypertrophic Cardiomyopathy Centre and Research Institute at Tufts Medical Centre. I'm also Co-Director of the Chanin T. Mast Hypertrophic Cardiomyopathy Centre in Morristown, New Jersey and Morristown Medical Centre. And the study that we're going to be talking about today is Redwood-HCM. Unmet need in the treatment of hypertrophic cardiomyopathy (HCM) So the focus of this trial and study, Redwood-HCM, is on the obstructive form of HCM.
Remote Monitoring May Reduce HFrEF Adverse Events
- Hi, my name is Larry Allen. I'm a transplant cardiologist at the University of Colorado in Denver. What is the importance of MANAGE-HF? Patients with heart failure and reduced ejection fraction typically suffer from chronic symptoms. And it's a relapsing and remitting disease where patients are sometimes better and then have acute exacerbations of their illness. There's been much interest in trying to predict or anticipate those decompensations in patients.
Effect of SGLT1 2 Inhibitors in EF including HFrEF
Video ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF Published: 18 May 2021 Views: 419 Likes: 1 Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Deepak L Bhatt (Brigham and Women's Hospital, Boston, MA, US) discussed the latest data on the benefits of SGLT1/2 inhibition across the full spectrum of ejection fraction, including HFpEF. Recorded remotely from Boston and Hamilton, 2021. Editor: Mirjam Boros Videography: Tom Green
Biomechanics and Mechanobiology of Saphenous Vein Grafts
Within several weeks of use as coronary artery bypass grafts (CABG), saphenous veins (SV) exhibit significant intimal hyperplasia (IH). IH predisposes vessels to thrombosis and atherosclerosis, the two major modes of vein graft failure.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michael S.
Contact Michael S., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack